CME Group Inc. (CME) — RQD Stock Rating Cockpit
CME Group Inc. (CME) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Decent core business (41% profit margin), though cash flow growth is moderate rather than explosive right now.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.
JEV AI Jury Split (Battleground) on CME
3.5% ROIC with 41.0% gross margin and 3.95% FCF yield.
Altman-Z 0.55 and Piotroski 8/9 pass balance-sheet audit.
Put/Call 0.75x with 22/40 institutional & insider flow.
- ✓Established market leader in Financials with deep daily trading liquidity.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live CME Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
CME Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CME today. View full Setup Ledger →
CME Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell CME stock right now?
CME Group Inc. (CME) currently earns a Roarable Rating of C- (Hold — HOLD) with 61/100 RQD Confidence. Solid 41% profit margin (4% return on capital), mixed timing at 26x P/E—hold if owned, no rush to chase.
What is CME's 12-month price target and RQD AI Jury consensus?
CME's 12-month base price target is $300.42 (range $234.33 to $354.5), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.